BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, June 6, 2026
Home » Blogs » BioWorld MedTech Perspectives » No excuses, get an EHR!

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

Medical technology / Imaging

No excuses, get an EHR!

July 20, 2012
By Amanda Pedersen

An acquaintance of mine who, like me, has inflammatory bowel disease, received a call recently from her local hospital informing her they had lost her MRI images. They found them, but she is concerned they will have to retake them anyway because at this point her images are no longer current enough for the doctor to make an informed treatment decision.

This is a prime example of why all hospitals should use electronic health records (EHRs). At a time when health IT (HIT) companies are cropping up faster than Starbucks coffee shops, and the federal government is handing out incentive funds to those hospitals who use electronic records, there is truly no excuse for not having an EHR system in place.

Asking patients to retake an MRI simply because they can’t keep their records together is not only inconvenient for the patient but extremely inefficient for the hospital. Assuming this sort of thing happens regularly, these are dollars the hospital is flushing away that could be invested in an EHR system.

Sure, there are initial costs involved with installing a reliable EHR system, but many of these costs are reimbursable under the American Recovery and Reinvestment Act and most HIT companies are eager to guide clients through the meaningful use requirements. It makes the company look good and it recovers critical funds for the hospitals to put to other uses, like saving lives.

Just as one example, we recently reported in Medical Device Daily that a financially-strapped 319-bed county hospital in California went live on Medsphere Systems’ OpenVista open source EHR. That hospital is expected, according to Medsphere, to receive “substantially more” in federal reimbursement than the five-year costs to acquire the system. It makes sense not only from a patient care standpoint but from a financial perspective also.

Medsphere President/CEO Irv Lichtenwald called the move a compelling example of responsible decision-making, and I agree. “Especially in these troubled economic times, public hospitals can still improve care without making financial matters worse for local government,” Lichtenwald said.

And of course Medsphere is not alone in the HIT market, the firm has plenty of competitors, all more than happy to help private and public hospitals alike experience similar financial gains by implementing these invaluable electronic records systems.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 2, 2026
  • Janssen Pharmaceutica reports new TMEM175 activators

    BioWorld Science
    Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...
  • Person holding stomach in pain

    Cancer specter looming, Abtect effect in UC wallops Abivax

    BioWorld
    Although analysts liked the data – calling them “truly amazing” and “transformational” – Wall Street apparently had qualms about three cancer cases that turned up...
  • Hepatitis B virus rendering

    EASL spotlight: TUNE-401 advances epigenetic silencing in HBV

    BioWorld
    Several presentations at EASL highlight a new generation of therapies coming into view, with the work from Tune Therapeutics Inc. standing out as one of the most...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing